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Abstract
Germline genetic variants have been identified, which predispose individuals and families to develop melanoma. Tumor
thickness is the strongest predictor of outcome for clinically localized primary melanoma patients. We sought to determine
whether there is a heritable genetic contribution to variation in tumor thickness. If confirmed, this will justify the search for
specific genetic variants influencing tumor thickness. To address this, we estimated the proportion of variation in tumor
thickness attributable to genome-wide genetic variation (variant-based heritability) using unrelated patients with measured
primary cutaneous melanoma thickness. As a secondary analysis, we conducted a genome-wide association study (GWAS)
of tumor thickness. The analyses utilized 10 604 individuals with primary cutaneous melanoma drawn from nine GWAS
datasets from eight cohorts recruited from the general population, primary care and melanoma treatment centers.
Following quality control and filtering to unrelated individuals with study phenotypes, 8125 patients were used in the
primary analysis to test whether tumor thickness is heritable. An expanded set of 8505 individuals (47.6% female) were
analyzed for the secondary GWAS meta-analysis. Analyses were adjusted for participant age, sex, cohort and ancestry. We
found that 26.6% (SE 11.9%, P = 0.0128) of variation in tumor thickness is attributable to genome-wide genetic variation.
While requiring replication, a chromosome 11 locus was associated (P < 5 × 10−8) with tumor thickness. Our work indicates
that sufficiently large datasets will enable the discovery of genetic variants associated with greater tumor thickness, and
this will lead to the identification of host biological processes influencing melanoma growth and invasion.
Introduction
Cutaneous melanoma (hereafter melanoma) is a potentially
fatal skin cancer resulting from the uncontrolled growth of
melanocytes, the pigment-producing cells of the skin. In 2019,
in Australia, there were estimated to be over 38 000 new cases of
melanoma (15 000 invasive) and nearly 2000 deaths, and in the
United States an estimated 192 000 cases of melanoma (97 000
invasive) with over 7000 deaths (1,2).
Tumor thickness, measured from the top of the epidermal
granular layer to the deepest point of tumor invasion, is the
single strongest predictive factor for mortality in clinically local-
ized primary cutaneous melanoma and widely used in disease
staging and prognostication (3–5). It is not yet known whether
primary melanoma thickness at the time of initial diagnosis is
influenced by heritable factors. Beyond the time of presenta-
tion for biopsy/excision of the lesion, factors such as invasion
potential, growth rate and immunosurveillance are likely to be
relevant to tumor thickness at presentation, and these may be
influenced by host germline characteristics (6–9).
Previous investigations have identified a limited number of
potential loci associated with primary melanoma tumor thick-
ness including at MMP1, FGFR4, VDR and loci previously associ-
ated with melanoma risk e.g. MC1R (10–16). No loci have been
validated independently. Two genome-wide association studies
(GWAS) of primary melanoma tumor thickness did not iden-
tify any genetic variants that were significant after multiple
testing correction (17,18). These findings are summarized in
Supplementary Material, Table S1.
Using over 8000 patients with primary cutaneous melanoma
from eight cohorts (Table 1), we sought to determine whether
heritable genetic factors influence melanoma tumor thickness
and the extent of such influence. Due to the possible impact
of shared environment on tumor thickness, and the increased
surveillance from diagnosis of melanoma in a close relative,
our analysis used distantly related individuals to remove this
potential for confounding (19–24). Confirmation that germline
genetic variation influences primary melanoma tumor thick-
ness would imply that, with a sufficiently large dataset, specific
genetic variants associated with greater tumor thickness can
be identified. Identifying these genetic variants, and the genes
they influence, will lead to a better understanding of the host
biological processes that are important for the growth and inva-
sion of melanoma.
Results
Contribution of genome-wide germline genotype to
variation in tumor thickness
Age- and sex- adjusted residuals of natural log transformed
tumor thickness were generated, and GREML-LDMS-I (23) was
used to determine the contribution of genome-wide germline
variants with a minor allele frequency > 0.001 to tumor thickness
variation (heritability, h2SNPs, Supplementary Material, Fig. S1,
Supplementary Material, Fig. S2, Methods).
In the combined dataset (N = 8125) with the first six ancestry
principal components and an individual cohort membership
variable fitted as covariates, tumor thickness h2SNP was
0.266 (standard error (SE) = 0.119, P = 0.0128). Analyzing the
age- and sex- corrected residuals of tumor thickness, and
fitting a dataset membership covariate, may not have com-
pletely accounted for all differences across datasets. However,
repeating analysis with rank normalized tumor thickness
residuals gave a similar h2SNP = 0.248 (SE = 0.119, P = 0.0188,
Supplementary Material, Fig. S3), indicating it is unlikely indi-
vidual study differences are driving the observed heritability.
The estimate from the random-effects meta-analysis of the
h2SNP for each discrete dataset calculated separately, while
losing power by not using genetic relationships across sample
sets, was consistent with the overall result (h2SNP = 0.264) but
with wider confidence intervals (SE = 0.158, P = 0.095; Methods,
Supplementary Material, Fig. S4).
Acral lentiginous melanoma tends to be diagnosed later and
have a greater thickness (25). Excluding 92 acral lentiginous
melanoma cases (histology data were available for all but the MD
Anderson Cancer Center (MDACC) cohort) did not meaningfully
change the results (h2SNP = 0.281, SE = 0.121, P = 0.0104).
Genome-wide association study of tumor thickness
As the h2SNP was significantly different to zero, indicating
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primary tumors, we therefore performed a linear regres-
sion GWAS of primary melanoma tumor thickness in each
dataset (Methods). Following the subsequent meta-analysis of
the individual genome-wide results, there was no evidence
of genomic inflation (N = 8505; genomic inflation λ = 1.00;
Supplementary Material, Fig. S5). Two genetic variants are
in linkage-disequilibrium (r2EUR = 0.69) at a single locus on
chromosome 11 reached genome-wide significance (Fig. 1). The
regional association plot is shown in Fig. 2. The lead variant was
rs183471242 (P = 3.56 × 10−9; Table 2). rs183471242 is in an intron
of the gene low-density lipoprotein receptor class A domain
containing 3 (LDLRAD3; Fig. 2). The distribution of natural
log transformed tumor thickness by genotype is displayed in
Fig. 3; the distribution of effect sizes across GWAS is shown
in Supplementary Material, Fig. S6. Both rs183471242 (G/A) and
rs566382949 (C/A) are rare (HRC v1.1 minor A allele 0.0098
and 0.0082, respectively), with the minor allele associated with
thicker tumors (Table 2, Fig. 3). Each minor allele of rs183471242
translates to a 1.423-fold increase on the transformed residuals
of tumor thickness.
As a sensitivity analysis, we performed the regression of
residual and rank normalized residual tumor thickness on
rs183471242 and rs566382949 in the same combined dataset
used for the GREML analysis (N = 8125), fitting the first six
PCs and study covariates in the model. Both SNPs remained
genome-wide significantly associated (P < 5 × 10−8) with tumor
thickness.
While none of the previously reported genetic variants
associated with primary tumor thickness reached genome-
wide significance in this study, the IRF4 functional genetic
variant rs12203592 was the most strongly associated (fixed
P = 6.50 × 10−4; Supplementary Material, Table S1) (10–18).
Discussion
Given inconsistency in identifying specific germline variants
associated with primary melanoma tumor thickness, we first
determined whether tumor thickness is heritable (that is, a
proportion of phenotypic variance can be explained by additive
genetic variants) (10–18). Traditionally, twin- or family-based
approaches are used to measure trait heritability, and do so
by assessing whether more closely related individuals tend to
have more similar phenotypes. However, shared environment
and behaviors can confound heritability estimates. For exam-
ple, diagnosis of melanoma in a relative can lead to increased
surveillance and earlier detection, which may influence thick-
ness (19,20,27–33). As a result, tumor thickness can become
inversely correlated to degree of genetic relationship, biasing
estimates of heritability. An effective alternative approach is
to estimate the genetic contribution to thickness using dis-
tantly related individuals, removing the potential confound-
ing between thickness and melanoma diagnosis in a relative
and/or earlier diagnosis (22). This alternative approach relies
on genome-wide single nucleotide polymorphism (SNP) arrays,
yielding an estimate of the variation attributable to these genetic
variants; this term is referred to as h2SNP. Since arrays do not
genotype all genetic variants, h2SNP represents a lower bound of
trait heritability.
Using a large collection of distantly related individuals with
melanoma (N = 8125 following filtering to remove individuals
such that there were no pairs where their relationship was
closer than identity-by-descent pi-hat = 0.025, Methods, Table 1),
we estimated the h2SNP for tumor thickness to be 0.266 (95% CI
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Figure 1. Manhattan plot of P-values from the meta-analysis of genome-wide association studies of tumor thickness. Negative Log10 of observed fixed-effects meta-
analysis P-values plotted by chromosome position. Red line indicates genome-wide significance (P = 5 × 10–8). Sample size is reported in Table 1.
Figure 2. Regional association plot for rs183471242. Negative Log10 of observed fixed-effects meta-analysis P-values plotted by chromosome position. Linkage
disequilibrium r2 of plotted SNPs with the lead SNP rs183471242 is displayed. Plot generated using LocusZoom (26).
analyses (Methods, Results). As this result indicates that pri-
mary melanoma tumor thickness is heritable, it shows that with
sufficiently well-powered cohorts, it will be possible to identify
specific genetic variants associated with tumor thickness.
Following confirmation that tumor thickness is heritable, we
used the complete dataset to perform a GWAS meta-analysis,
identifying two genetic variants in a locus on chromosome 11
at genome-wide significance (P < 5 × 10−8). As tumor thickness
values were natural log transformed prior to analysis, the effect
size for each minor allele of rs183471242 is associated with a
1.42-fold higher tumor thickness. rs183471242 is rare (minor
A allele frequency 0.0098) with 190 heterozygote GA and 1
homozygous AA samples (Fig. 3). This variant appears to be
rarer in non-European populations with an MAF of 0.0018 in
African populations and not observed in 780 East Asian samples
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Table 2. Genetic variants associated with tumor thickness following multiple testing correction
CHR BP rsID EA/NEA EA FREQ P BETA Q I2
rs183471242 11 36 019 025 A/G 0.0098 3.56 × 10−9 0.353 0.81 0
rs566382949 11 36 068 615 A/C 0.0082 1.58 × 10−8 0.382 0.97 0





rs183471242 0.598 0.501 0.443 0.241 0.389 0.459 0.093 0.229 0.369
rs566382949 0.326 0.518 0.418 0.302 0.232 0.541 0.240 0.406 0.435
We report hg19 chromosome (CHR) and base pair (BP) positions for genetic variants (rsID). The effect allele (EA) and non-effect allele (NEA) are provided, as is the HRC
frequency of the EA (EA FREQ). The fixed effects meta-analysis P (P), effect size (BETA) on the residuals of fitting age and sex on natural log transformed tumor thickness;
the first six ancestry principal components were included as covariates in the regression (Methods). As there is no heterogeneity (Q, I2) the random effects meta-analysis
values are identical. We also report effect size estimates for individual datasets. The distribution of these measures is displayed in Supplementary Material, Fig. S6.
Q-MEGA samples were analyzed by HumanHap610 (610 k) and Omni1-Quad (omni) genotyped array used (Methods). Sample size is reported in Table 1.
the closest gene is not always the target of associated genetic
variants. However, interrogation of public gene expression and
annotation resources do not reveal an obvious functional target
for these genetic variants (35–38). LDLRAD3 is a member of the
LDL receptor family and may play a role in activating genes
involved in protein ubiquitination (39). Neither of these two
genetic variants were associated (P > 0.05) with ease of tanning,
childhood sunburns or skin and hair color in the UK Biobank
(data not shown), melanoma risk, nor nevus count (40,41). While
none of the previously reported genetic variants associated with
tumor thickness reached a P-value<5 × 10−8, the IRF4 functional
genetic variant rs12203592 was the most strongly associated
(P = 6.51 × 10−4, I2 = 36.4%, Supplementary Table 1). The direction
of effect is the same as in the previous report from the Western
Australian Melanoma Heath Study; this dataset is included in
this analysis (10). The IRF4 SNP rs12203592 has been associated
with risk of melanoma (42,43). It is not clear to what extent
genetic variants associated with cancer risk influence outcome
(e.g. there is no overlap between genetic variants associated
with risk or survival for lung cancer (44) or breast cancer (45)),
and as such, it is unclear if we would expect the other known
melanoma risk variants (e.g. in MC1R) to associate with tumor
thickness in a larger analysis.
The thickness of a tumor at diagnosis is the outcome of its
duration and rate of growth. In practice, these two factors are
hard to assess post detection and unknown before diagnosis,
and as a result, the relative importance of either is unclear (6,27–
29,33,46). Our work shows that germline genetic variation plays
a role in thickness. While the specific mechanisms are yet to
be determined, host germline genetic variants may influence
tumor growth rate, immunosurveillance or characteristics relat-
ing to time to discovery such as appearance of the tumor or
the assiduousness of personal skin checks. While different sub-
types of melanoma grow at different rates, accurate heritability
estimates require very large sample sizes; thus (and to avoid
repeated multiple testing), we have not performed subtype spe-
cific analyses beyond excluding the acral subtype. Other factors
may influence tumor thickness. Higher body mass index (BMI)
has been associated with greater thickness; however, fitting a
trait that is itself genetically controlled as a covariate can bias
genetic association towards false positives and we hence did not
include this in our analysis (47–50).
While both our heritability estimate and the genetic vari-
ants associated with tumor thickness following correction for
multiple testing require replication in a sufficiently large dataset,
these findings indicate germline variants impact tumor devel-
opment, a strong predictor of melanoma outcome. Discovery of
specific genetic variants will enable identification of host biolog-
ical processes influencing melanoma growth and invasion.
Materials and Methods
Dataset descriptions
Overall demographics of contributing datasets are summarized
in Table 1. Full descriptions of each contributing dataset can be
found in the Supplementary Material, Note.
Quality control, cleaning and imputation of
genome-wide genotype data
PLINK v1.9 and R 3.3.2 (51,52) were used for quality control and
cleaning of genome-wide genotype data. Genotyped variants
were filtered out if they had a minor allele frequency < 0.01,
Hardy–Weinberg equilibrium P-value<5 × 10−4 in cancer-free
individuals (where melanoma cases were genotyped/cleaned
in concert with healthy individuals) or < 5 × 10−10 in those with
melanoma. To remove samples with low-quality DNA, or other
issues that may impact analysis (e.g. sample contamination or
inbreeding) (53), individuals were excluded if they had missing-
ness >0.03, heterozygosity more than three standard deviations
(SDs) from the rest of the population, a mismatch between
recorded sex and X chromosome determined sex or were
considered non-European. European ancestry was determined
by principal components analysis using 1000 Genomes European
populations as a reference set (54). Individuals more than three
SDs from the mean of principal component 1 or 2 were excluded.
Relatedness across and within genotyped sets was measured by
identity-by-descent pi-hat scores using PLINK (51). For pairs with
pi-hat>0.15, the individual with the highest missing genotype
rate was dropped.
The Michigan Imputation Server was used to impute individ-
uals (Table 1) to the Haplotype Reference Consortium panel (HRC
version 1), and genetic variants with an imputation quality score
RSQ > 0.3, minor allele frequency > 0.001 and minor allele count
>3 were retained for analysis (55,56). While the approach we
have used to determine the genetic contribution to melanoma
thickness (see below) is robust to imputation quality, RSQ > 0.3
excludes potentially poorly imputed genetic variants (23).
Cleaning and normalization of tumor thickness
Research participant demographics are presented in Table 1.
Primary melanoma tumor thickness measurements were
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Figure 3. Distribution of natural log transformed primary cutaneous melanoma tumor thickness by rs183471242 genotypes. Data are reported for the combined meta-
analysis of all studies for this genetic variant (8505 individuals). For plotting purposes, we display the natural log transform of tumor thickness by genotype rather than
the residuals of tumor thickness as used in the heritability estimation and GWAS. In total, there are 8310 homozygous GG, 194 AG and a single AA genotype (HRC v1.1
minor A allele 0.0098). AG and AA genotypes have been plotted together. Distribution of tumor thickness is described using a notched whisker plot (blue) where the
midpoint of the notch is the median, and the 95% confidence interval of that median is represented by the notched region. The boundaries of the boxed area extend to
the first and third quartiles. The whiskers represent the 1.5 × the interquartile range. The same data are displayed twice with differing secondary layers to display the
distribution of tumor thickness residuals; the first is a violin plot, and the second displays the individual results. The individual with the AA genotype had a primary
tumor thickness of 0.5 mm, and their position is indicated by an arrow in the second plot.
melanomas, the first primary tumor was used. The distri-
bution of tumor thickness is reported in Table 1. As tumor
thickness is not normally distributed, measurements were
natural log transformed. Age- and sex-adjusted residuals of
transformed tumor thickness were used for analyses. The
distribution of tumor thickness between cohorts is significantly
different (P < 2 × 10−16 from ANOVA with age and sex fitted as
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comparisons are reported in Supplementary Material, Table S2.
As a result, analyses were performed with a cohort variable fitted
and as a sensitivity analysis repeated with rank transformation
of tumor thickness.
Estimation of heritability for a complex trait
We sought to estimate the heritability (h2, defined as the pro-
portion of phenotypic variance explained by additive genetic
variants) for primary cutaneous melanoma tumor thickness.
Heritability is traditionally estimated from family data, with high
heritability inferred when individuals who are closely related
have more similar phenotypes than those who are more dis-
tantly related. An alternative approach to family-based methods
is to estimate the genetic contribution to thickness using only
distantly related individuals to estimate heritability attributable
to SNPs, h2SNP (22).
Early methods for estimating h2SNP such as genome-based
restricted maximum likelihood as implemented in the Genome-
wide Complex Trait Analysis software use only directly geno-
typed variants (22). However, imputation of genetic variants not
present on genotyping arrays can improve discovery power and
resolution for standard genome-wide association studies and
heritability estimates (21,56). In aggregate, rare variants capture
on average one third of the h2SNP, and their inclusion can yield
more accurate h2SNP estimates (21,24).
The h2SNP was determined using an extension of the genome-
based restricted maximum likelihood approach designed for
imputed data, GREML-LDMS-I, as implemented in the Genome-
wide Complex Trait Analysis software (21–23). GREML-LDMS
was used recently to determine that ∼50% of the heritability of
height is accounted for by genetic variants with a minor allele
frequency between 0.0001 and 0.1 (57). GREML-LDMS-I is made
robust to the (unknown) underlying trait genetic architecture
by dividing input genetic variants into bins based on their
minor allele frequency and degree of linkage disequilibrium
(23,24). This is important as incorrect modeling of the underlying
genetic architecture can lead to under- or over-estimation of
h2SNP (21,24).
Construction of a combined imputed dataset for
array-based heritability estimates
Imputed dosage data from the Michigan Imputation Server in
variant-call format were converted to best guess format (geno-
type dosage ≤0.5 as 0, 0.5–1.5 as 1 and >1.5 as 2) and merged
into a single combined dataset using PLINK v1.91.4 beta3 (21,51).
PLINK binary files were converted into a genetic relationship
matrix by Genome-wide Complex Trait Analysis v1.91.4 (21,22).
To ensure only distantly related individuals were included, the
merged dataset was filtered such that no pair had identify-by-
descent pi-hat>0.025 (21,22) (Table 1; final combined sample size
of 8125).
We used GREML-LDMS-I to estimate h2SNP for genetic vari-
ants binned by minor allele frequency (0.4–0.5, 0.3–0.4, 0.2–0.3,
0.1–0.2, 0.01–0.1, 0.001–0.01) and linkage-disequilibrium quar-
tile. Linkage-disequilibrium scores were estimated for individual
genetic variants rather than regions of variants, as this approach
produces unbiased estimates in the presence of all possible
genetic architectures (21).
Spurious genetic similarities (e.g. ancestry, cohort or batch
effects) can bias h2 estimates (21). To address this, we fitted
the first six ancestry principal components and a dataset mem-
bership variable (a binary yes/no variable for membership in a
given cohort) in the GREML-LDMS-I analyses. As a sensitivity
analysis, we repeated analyses following rank normalization of
tumor-thickness residuals within each cohort.
While the larger merged dataset increased power by leverag-
ing distant genetic relationships across and between individual
datasets, it may have introduced bias due to subtle differences
in ancestry, tumor thickness or genotyping methods within
each individual dataset. As an additional sensitivity analysis, we
estimated h2SNP in the individual imputed datasets (filtered to
identity-by-descent pi-hat<0.025 within the individual dataset
rather than across all datasets) using standard genome-based
restricted maximum likelihood (22). The binned GREML-LDMS-I
approach was not applied to individual datasets as they were too
small. Individual dataset’s h2SNP estimates were then combined
using a random effects meta-analysis using the metafor package
in R (58). metafor was also used to generate forest plots.
Genome-wide association study of tumor thickness
To identify specific genetic variants associated with tumor thick-
ness, within each individual dataset, residual tumor thickness
was regressed on imputed genome-wide genotype dosages with
the first six ancestry principal components included as covari-
ates. Individual dataset results were further filtered by removing
variants with an extreme effect size estimate (>2 or < −2 on
the rank-normalized residuals of natural log-transformed tumor
thickness; as a reference, in the Australian Melanoma Family
Study (AMFS) dataset, this removes genetic variants with an
effect size estimate >8 SDs from an effect size of 0). Genome-
wide association results for each individual dataset were com-
bined by inverse variance-weighted fixed effects meta-analysis
in PLINK v1.91.4 beta3 (51). The total number of genetic variants
tested was 13 517 544. Genetic variants were deemed significant
if their P-value was less than a genome-wide multiple testing
corrected threshold of P < 5 × 10−8.
In a GWAS, the majority of genetic variants are not expected
to be associated and their X2 distribution should match the
null and have a median of ∼0.456 (59). We report the genomic
inflation λ, the median meta-analysis X2/0.456.
Additional analysis methods are reported in the supplemen-
tary note.
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